Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy

Cancer Letters

Volumn 324, Issue 1, 2012, Pages 42-47

  Tsunashima, Ryo ^a   Naoi, Yasuto ^a   Kishi, Kazuki ^b   Baba, Yosuke ^b   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Nakayama, Takahiro ^a   Shimazu, Kenzo ^a   Kim, Seung Jin ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

95 Gene classifier; Breast cancer; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; LETROZOLE; LEUPRORELIN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CLASSIFIER; DISTANT RELAPSE FREE SURVIVAL; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR BIOPSY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84864056624     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.017     Document Type: Article

References (24)

1. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
2. Habel L.A., Shak S., Jacobs M.K., Capra A., Alexander C., Pho M., Baker J., Walker M., Watson D., Hackett J., Blick N.T., Greenberg D., Fehrenbacher L., Langholz B., Quesenberry C.P. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006, 8:R25.
3. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
4. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
5. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van de Vijver M.J., Bergh J., Piccart M., Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 2006, 98:262-272.
6. Naoi Y., Kishi K., Tanei T., Tsunashima R., Tominaga N., Baba Y., Kim S.J., Taguchi T., Tamaki Y., Noguchi S. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res. Treat. 2011, 128:633-641.
7. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., Ravdin P., Bugarini R., Baehner F.L., Davidson N.E., Sledge G.W., Winer E.P., Hudis C., Ingle J.N., Perez E.A., Pritchard K.I., Shepherd L., Gralow J.R., Yoshizawa C., Allred D.C., Osborne C.K., Hayes D.F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet. Oncol. 2010, 11:55-65.
8. Chang J.C., Makris A., Gutierrez M.C., Hilsenbeck S.G., Hackett J.R., Jeong J., Liu M.L., Baker J., Clark-Langone K., Baehner F.L., Sexton K., Mohsin S., Gray T., Alvarez L., Chamness G.C., Osborne C.K., Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. 2008, 108:233-240.
9. Mook S., Schmidt M.K., Viale G., Pruneri G., Eekhout I., Floore A., Glas A.M., Bogaerts J., Cardoso F., Piccart-Gebhart M.J., Rutgers E.T., van't Veer L.J. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 2009, 116:295-302.
10. Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., van de Vijver M.J., Koornstra R.H., Bueno-de-Mesquita J.M., Linn S.C., van't Veer L.J. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res. Treat. 2010, 120:655-661.
11. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., Vrancken Peeters M.J., van Tinteren H., van't Veer L.J., Rodenhuis S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 2010, 119:551-558.
12. Filho O.M., Ignatiadis M., Sotiriou C. Genomic grade index: an important tool for assessing breast cancer tumor grade and prognosis. Crit. Rev. Oncol. Hematol. 2011, 77:20-29.
13. Liedtke C., Hatzis C., Symmans W.F., Desmedt C., Haibe-Kains B., Valero V., Kuerer H., Hortobagyi G.N., Piccart-Gebhart M., Sotiriou C., Pusztai L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J. Clin. Oncol. 2009, 27:3185-3191.
14. Naoi Y., Kishi K., Tanei T., Tsunashima R., Tominaga N., Baba Y., Kim S.J., Taguchi T., Tamaki Y., Noguchi S. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011, 117:3682-3690.
15. Sakamoto G., Inaji H., Akiyama F., Haga S., Hiraoka M., Inai K., Iwase T., Kobayashi S., Sakamoto G., Sano M., Sato T., Sonoo H., Tsuchiya S., Watanabe T. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005, 12(Suppl):S1-27.
16. Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., Vidaurre T., Holmes F., Souchon E., Wang H., Martin M., Cotrina J., Gomez H., Hubbard R., Chacon J.I., Ferrer-Lozano J., Dyer R., Buxton M., Gong Y., Wu Y., Ibrahim N., Andreopoulou E., Ueno N.T., Hunt K., Yang W., Nazario A., DeMichele A., O'Shaughnessy J., Hortobagyi G.N., Symmans W.F. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011, 305:1873-1881.
17. Ivshina A.V., George J., Senko O., Mow B., Putti T.C., Smeds J., Lindahl T., Pawitan Y., Hall P., Nordgren H., Wong J.E., Liu E.T., Bergh J., Kuznetsov V.A., Miller L.D. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66:10292-10301.
18. Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., Ellis P., Harris A., Bergh J., Foekens J.A., Klijn J.G., Larsimont D., Buyse M., Bontempi G., Delorenzi M., Piccart M.J., Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 2007, 25:1239-1246.
19. Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., Reid J.F., Daidone M.G., Pierotti M.A., Berns E.M., Jansen M.P., Foekens J.A., Delorenzi M., Bontempi G., Piccart M.J., Sotiriou C. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
20. Oshima K., Naoi Y., Kishi K., Nakamura Y., Iwamoto T., Shimazu K., Nakayama T., Kim S.J., Baba Y., Tamaki Y., Noguchi S. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. Cancer Lett. 2011, 307:149-157.
21. Gyorffy B., Benke Z., Lanczky A., Balazs B., Szallasi Z., Timar J., Schafer R. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res. Treat. 2012, 132:1025-1034.
22. Dowsett M., Cuzick J., Wale C., Forbes J., Mallon E.A., Salter J., Quinn E., Dunbier A., Baum M., Buzdar A., Howell A., Bugarini R., Baehner F.L., Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 2010, 28:1829-1834.
23. Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., Parker J.S., Luo J., DeSchryver K., Allred D.C., Esserman L.J., Unzeitig G.W., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Watson M.A., Leitch M., Hunt K., Olson J.A. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J. Clin. Oncol. 2011, 29:2342-2349.
24. Miyake T., Nakayama T., Naoi Y., Yamamoto N., Otani Y., Kim S.J., Shimazu K., Shimomura A., Maruyama N., Tamaki Y., Noguchi S. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 2012, 103:913-920.